-
Ibritumomab tiuxetan (pronounced /ɪbrɪˈtuːmoʊmæb taɪˈʌksɛtæn/), sold
under the
trade name Zevalin, is a
monoclonal antibody radioimmunotherapy treatment...
- A
radioligand is a
microscopic particle which consists of a
therapeutic radioactive isotope and the cell-targeting
compound - the ligand. The
ligand is...
-
Monoclonal antibody ibritumomab conjugated with tiuxetan...
- Iodine-131-sodium
iodide Hyperthyroidism and
thyroid cancer Yttrium-90-
ibritumomab tiuxetan (Zevalin) and Iodine-131-tositumomab (Bexxar)
Refractory lymphoma...
- 2002, the
United States Food and Drug
Administration (FDA)
approved ibritumomab tiuxetan (Zevalin),
which is an anti-CD20
monoclonal antibody conjugated...
-
radioisotope yttrium-90 (90Y) is used to
label drugs such as
edotreotide and
ibritumomab tiuxetan for the
treatment of
various cancers,
including lymphoma, leukemia...
-
Yttriga yttrium (Y 90)
clivatuzumab tetraxetan (USAN)
yttrium (Y 90)
ibritumomab tiuxetan (INN)
yttrium bromatum yttrium fluoratum yttrium iodide yttrium...
- radiosynthesis/
radiolabeling process,
which is
tailored to the
desired product.
Ibritumomab Tiuxetan;
Zevalin - For
dosimetry estimates prior to 90Y immunotherapy...
-
neoplasm or is not
accessible in
normal cells. 131I
tositumomab and 90Y
ibritumomab tiuxetan were the
first agents of radioimmunotherapy, and they were approved...
-
target of the mAbs rituximab, ocrelizumab, obinutuzumab, ofatumumab,
ibritumomab tiuxetan, tositumomab, and ublituximab,
which are all
active agents in...
